AlanBreierMD

Professor of Psychiatry and assumed respoinsibilities as Chief of the Psychotic Disorders Program and Director of Research at Larue Carter hospital

Join to view full profile

Are you Dr. Breier?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 64 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
355 W 16th St Ste 2800
Indianapolis, IN 46202
Phone+1 317-963-7300

Fax+1 317-943-7325
Is this information wrong?

Summary

Dr. Alan Breier, MD is a board certified neurologist in Indianapolis, Indiana. He is currently licensed to practice medicine in Indiana, District of Columbia, and Maryland. He is affiliated with Eskenazi Health.

Education & Training

National Institutes of Health Clinical CenterResidency, Psychiatry, 1984 - 1987
Yale-New Haven Medical CenterResidency, Psychiatry, 1981 - 1984
Yale-New Haven Medical CenterInternship, Transitional Year, 1980 - 1981
University of Cincinnati College of MedicineClass of 1980

Certifications & Licensure

IN State Medical License 1997 - 2025
MD State Medical License 1984 - 1998
DC State Medical License 1990 - 1997
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects Start of enrollment: 2008 Sep 01
Terminated
Phase 2
Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone Start of enrollment: 2010 Jul 01
Completed
Phase 3
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Start of enrollment: 2011 May 01
Completed
Phase 4
Fingolimod in Schizophrenia Patients Start of enrollment: 2013 Jan 01
Completed
Phase 2
The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia Start of enrollment: 2013 Jun 01
Terminated
Phase 2
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia Start of enrollment: 2014 Mar 26
Completed
Phase 2
Integrated Metacognitive Therapy in First Episode Psychosis Start of enrollment: 2014 May 01
Completed
Not Applicable
rTMS in First Episode Psychosis Start of enrollment: 2014 Apr 30
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Muscarinic Receptor Activators as Novel Treatments for Schizophrenia.
Steven M Paul, Samantha E Yohn, Stephen K Brannan, Nichole M Neugebauer, Alan Breier> ;Biological Psychiatry. 2024 Mar 25
Data-driven, connectome-wide analysis identifies psychosis-specific brain correlates of fear and anxiety.
Brandee Feola, Adam Beermann, Karlos Manzanarez Felix, Michael Coleman, Sylvain Bouix, Kathryn E Lewandowski, Dost Öngür, Martha E Shenton, Roscoe O Brady Jr, Jennifer...> ;Molecular Psychiatry. 2024 Mar 19
Isolation of Distinct Networks Driving Action and Cognition in Psychomotor Processes.
Ward, H. B., Alexandra B Moussa-Tooks, Adam Beermann, Karlos Manzanarez Felix, Michael Coleman, Sylvain Bouix, Daphne Holt, Kathryn E Lewandowski, Dost Öngür, Alan Bre...> ;Biological Psychiatry. 2024 Mar 5
1 citations
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, p...
Kaul, I., Sawchak, S., Zhu, H., Miller, A., Paul, S., Brannan, S., Correll, C., Kakar, R., Breier, A.> ;Lancet. 2024 Jan 13
5 citations
Normative Modeling of Brain Morphometry Across the Lifespan Using CentileBrain: Algorithm Benchmarking and Model Optimization.
Ge, R., Yu, Y., Qi, Y., Fan, Y., Chen, S., Gao, C., Haas, S., Modabbernia, A., New, F., Agartz, I., Asherson, P., Ayesa-Arriola, R., Banaj, N., Banaschewski, T., Baume...> ;Biorxiv. 2023 Dec 2
Early phase psychosis and criminal conviction in United States adults.
Kyle D Webster, Tracy D Gunter, Jenifer L Vohs, Alan Breier> ;Early Intervention in Psychiatry. 2023 Nov 29
8 citations
Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results.
Alan Breier, Stephen K Brannan, Steven M Paul, Andrew C Miller> ;Psychopharmacology. 2023 May 1
10 citations
A preliminary choroid plexus volumetric study in individuals with psychosis.
Olcay Senay, Magdalena Seethaler, Nikos Makris, Edward Yeterian, Jarrett Rushmore, Kang Ik K Cho, Elizabeth Rizzoni, Carina Heller, Ofer Pasternak, Filip Szczepankiewi...> ;Human Brain Mapping. 2023 Apr 15
14 citations
Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, a...
Peter J Weiden, Alan Breier, Sarah Kavanagh, Andrew C Miller, Stephen K Brannan, Steven M Paul> ;The Journal of Clinical Psychiatry. 2022 May 11
25 citations
Cell type-specific manifestations of cortical thickness heterogeneity in schizophrenia.
Maria A Di Biase, Michael P Geaghan, William R Reay, Jakob Seidlitz, Cynthia Shannon Weickert, Alice Pébay, Melissa J Green, Yann Quidé, Joshua R Atkins, Michael J Col...> ;Molecular Psychiatry. 2022 Apr 1
3 citations
Semantic and phonetic similarity of verbal fluency responses in early-stage psychosis.
Nancy B Lundin, Michael N Jones, Evan J Myers, Alan Breier, Kyle S Minor> ;Psychiatry Research. 2022 Mar 1
3 citations
Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial
Steven D. Targum, Christopher J. Murphy, Alan Breier, Stephen K. Brannan> ;Journal of Psychiatric Research. 2021 Oct 21
12 citations
Effects of fingolimod, a sphingosine-1-phosphate (S1P) receptor agonist, on white matter microstructure, cognition and symptoms in schizophrenia.
Michael M. Francis, Tom A. Hummer, Emily Liffick, Jenifer L. Vohs, Nikki Mehdiyoun, Andrew Visco, Ziyi Yang, Richard J. Kovacs, Ying Zhang, Alan Breier> ;Brain Imaging and Behavior. 2021 Aug 1
95 citations
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
Stephen K. Brannan, Sharon Sawchak, Andrew C. Miller, Jeffrey A. Lieberman, Steven M. Paul, Alan Breier> ;The New England Journal of Medicine. 2021 Feb 25
95 citations
Cortical thickness across the lifespan: Data from 17,075 healthy individuals aged 3-90 years
Sophia Frangou, Amirhossein Modabbernia, Steven Williams, Efstathios Papachristou, Gaelle E. Doucet, Ingrid Agartz, Moji Aghajani, Theophilus N. Akudjedu, Anton Albaje...> ;Human Brain Mapping. 2021 Feb 17
51 citations
Subcortical volumes across the lifespan: Data from 18,605 healthy individuals aged 3-90 years
Danai Dima, Amirhossein Modabbernia, Efstathios Papachristou, Gaelle E. Doucet, Ingrid Agartz, Moji Aghajani, Theophilus N. Akudjedu, Anton Albajes-Eizagirre, Dag Alnæ...> ;Human Brain Mapping. 2021 Feb 11
8 citations
Exposure to Epstein Barr virus and cognitive functioning in individuals with schizophrenia.
Faith Dickerson, Emily Katsafanas, Andrea Origoni, Amalia Squire, Sunil Khushalani, Theresa Newman, Kelly C. Rowe, Cassie Stallings, Christina L.G. Savage, Kevin Sween...> ;Schizophrenia Research. 2021 Jan 12
55 citations
Greater male than female variability in regional brain structure across the lifespan
Lara M. Wierenga, Gaelle E. Doucet, Danai Dima, Ingrid Agartz, Moji Aghajani, Theophilus N. Akudjedu, Anton Albajes-Eizagirre, Dag Alnæs, Kathryn I. Alpert, Ole A. And...> ;Human Brain Mapping. 2020 Oct 12
12 citations
Relationship of Metacognition and Insight to Neural Synchronization and Cognitive Function in Early Phase Psychosis.
Bethany L. Leonhardt, Jenifer L. Vohs, Lisa A. Bartolomeo, Andrew Visco, William P. Hetrick, Amanda R. Bolbecker, Alan Breier, Paul H. Lysaker, Brian F. O'Donnell> ;Clinical EEG and Neuroscience. 2020 Jul 1
4 citations
Prism Adaptation Deficits in Schizophrenia.
Lisa A. Bartolomeo, Yong-Wook Shin, Hannah J. Block, Amanda R. Bolbecker, Alan Breier, Brian F. O'Donnell, William P. Hetrick> ;Schizophrenia Bulletin. 2020 Mar 17
25 citations
Functional network connectivity in early-stage schizophrenia
Tom A. Hummer, Matthew G. Yung, Joaquín Goñi, Susan K. Conroy, Michael M. Francis, Nicole F. Mehdiyoun, Alan Breier> ;Schizophrenia Research. 2020 Feb 7
9 citations
Relationship of auditory electrophysiological responses to magnetic resonance spectroscopy metabolites in Early Phase Psychosis.
Lisa A. Bartolomeo, Andrew M. Wright, Ruoyun E. Ma, Tom A. Hummer, Michael M. Francis, Andrew Visco, Nicole F. Mehdiyoun, Amanda R. Bolbecker, William P. Hetrick, Ulri...> ;International Journal of Psychophysiology. 2019 May 23
17 citations
Internalized stigma in adults with early phase versus prolonged psychosis.
Ruth L. Firmin, Paul H. Lysaker, Lauren Luther, Philip T. Yanos, Bethany L. Leonhardt, Alan Breier, Jenifer L. Vohs> ;Early Intervention in Psychiatry. 2019 Aug 1
23 citations
Cognitive effects of bilateral high frequency repetitive transcranial magnetic stimulation in early phase psychosis: a pilot study.
Michael M. Francis, Tom A. Hummer, Jenifer L. Vohs, Matthew G. Yung, Andrew Visco, Nikki Mehdiyoun, Teresa C. Kulig, Miji Um, Ziyi Yang, Mehrdad Motamed, Emily Liffick...> ;Brain Imaging and Behavior. 2019 Jun 1
12 citations
Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study.
Alan Breier, Robert W. Buchanan, Deepak Cyril D'Souza, Keith H. Nuechterlein, Stephen R. Marder, Walter Dunn, Sheldon H. Preskorn, Matthew Macaluso, Brent E. Wurfel, G...> ;Schizophrenia Research. 2019 Apr 1
Join now to see all

Press Mentions

BTAI: Highlights from BXCL501 KOL Event…February 25th, 2021
BioXcel Therapeutics Forms Neuroscience Clinical Advisory Board to Support Global Development of BXCL501July 10th, 2018
Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical MeetingsMay 19th, 2017
Join now to see all

Hospital Affiliations

Eskenazi HealthIndianapolis, Indiana